Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL78947 | 1.00 | LMNA (0.48) | LMNAGAAKMT2APOLBSMN1; SMN2 | |
| SCHEMBL317779 | 1.00 | LMNA (0.48) | LMNAGAAKMT2APOLBSMN1; SMN2 | |
| Methylene Chloride SCHEMBL28127319 | 0.93 | LMNA (0.47) | LMNAGAAKMT2APOLBSMN1; SMN2 | |
| Methylene Chloride SCHEMBL28127317 | 0.93 | LMNA (0.47) | LMNAGAAKMT2APOLBSMN1; SMN2 | |
| SCHEMBL4939720 | 0.89 | KMT2A (0.42) | LMNAGAAKMT2APOLBCNR1 | |
| SCHEMBL4939718 | 0.89 | KMT2A (0.42) | LMNAGAAKMT2APOLBCNR1 | |
| SCHEMBL5026447 | 0.89 | KMT2A (0.42) | LMNAGAAKMT2APOLBCNR1 | |
| SCHEMBL2790715 | 0.87 | LMNA (0.43) | LMNAGAAKMT2APOLBSMN1; SMN2 | |
| SCHEMBL30948745 | 0.87 | LMNA (0.45) | LMNAGAAKMT2APOLBSMN1; SMN2 | |
| SCHEMBL6810038 | 0.87 | KMT2A (0.41) | LMNAGAAKMT2APOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731309-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260109714-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2026-04-23 | — | — | US | disclosed |
| EP-3897833-B1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMA (US) | 2026-02-04 | — | — | EP | disclosed |
| US-20250391519-A1 | CHEMICAL SYNTHESIS PLATFORM | UNIV GLASGOW COURT (GB) | 2025-12-25 | — | — | US | disclosed |
| US-20250262222-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE SWITZERLAND GMBH (CH) | 2025-08-21 | — | — | US | disclosed |
| US-12378216-B2 | Heteroaryl(heterocyclyl)methanol compounds useful in the treatment of hyperglycaemia | ATROGI AB (SE) | 2025-08-05 | — | — | US | disclosed |
| EP-4592295-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2025-07-30 | — | — | EP | disclosed |
| EP-4568967-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BeiGene Switzerland GmbH (CH) | 2025-06-18 | — | — | EP | disclosed |
| US-20250186456-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2025-06-12 | — | — | US | disclosed |
| EP-4563580-A1 | FUSED RING COMPOUND, PREPARATION METHOD THEREFOR AND MEDICINAL APPLICATION THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2025-06-04 | — | — | EP | disclosed |
| US-20090258918-A1 | EP4 receptor agonist, compositions and methods thereof | BILLOT XAVIER | 2009-10-15 | — | — | US | disclosed |
| US-20090258918-A1 | EP4 receptor agonist, compositions and methods thereof | BILLOT XAVIER | 2009-10-15 | — | — | US | disclosed |
| US-7256186-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-08-14 | — | — | US | disclosed |
| EP-1663975-A1 | NOVEL GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050085506-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2005-04-21 | — | — | US | disclosed |
| WO-2005028440-A1 | NOVEL GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-1315495-A2 | USE OF THREO-METHYLPHENIDATE COMPOUNDS TO ENHANCE MEMORY | Sention, Inc. (US) | 2003-06-04 | — | — | EP | disclosed |
| WO-2002017920-A2 | USE OF METHYLPHENIDATE COMPOUNDS TO ENHANCE MEMORY | SENTION, INC (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2002017919-A2 | USE OF THREO-METHYLPHENIDATE COMPOUNDS TO ENHANCE MEMORY | SENTION, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| US-4177346-A | 1,5-Disubstituted-2-pyrrolidones | PFIZER INC. (US) | 1979-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250262222-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | KRAS, NRAS, HRAS | LMNA 1705/4885GAA 1664/4885KMT2A 894/4885 |
| US-20250186456-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | KRAS, NRAS, TP53 | LMNA 3591/4885GAA 3169/4885KMT2A 2733/4885 |
| US-20260109714-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, HRAS | LMNA 4088/4885GAA 4554/4885KMT2A 2372/4885 |
| US-12378216-B2 | Heteroaryl(heterocyclyl)methanol compounds useful in the treatment of hyperglycaemia | SLC5A1, GPR119, SLC5A2 | LMNA 1919/4885GAA 336/4885KMT2A 1713/4885 |
| US-20090258918-A1 | EP4 receptor agonist, compositions and methods thereof | PTGER4, PTGER1, PTGER3 | LMNA 2379/4885GAA 4827/4885KMT2A 3696/4885 |
| US-20250391519-A1 | CHEMICAL SYNTHESIS PLATFORM | SET, CBS, COASY | LMNA 3787/4885GAA 416/4885KMT2A 1049/4885 |
| US-20050085506-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | LMNA 1578/4885GAA 310/4885KMT2A 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.